<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04965688</url>
  </required_header>
  <id_info>
    <org_study_id>U21-02-4401</org_study_id>
    <nct_id>NCT04965688</nct_id>
  </id_info>
  <brief_title>Systems Biology Guided Therapy for Breast Cancer Positive for Oestrogen Receptor After Aromatase Inhibitor and CDK Inhibition</brief_title>
  <acronym>SPOCK</acronym>
  <official_title>Systems Biology Guided Therapy for Breast Cancer Positive for Oestrogen Receptor After Aromatase Inhibitor and CDK Inhibition</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Inova Health Care Services</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>City of Hope Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Inova Health Care Services</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      There are several approved and guideline-recommended treatments for metastatic, estrogen&#xD;
      receptor-positive breast cancer that has progressed on an aromatase inhibitor and a CDK4/6&#xD;
      inhibitor. Right now, doctors do not have a good way of choosing between these treatments.&#xD;
      Scientists we work with have come up with ways to use the biology of the tumor to try to&#xD;
      predict which treatment is best. This study is being done to test if those predictions are&#xD;
      right and to learn more about these tumors to design better treatments in the future.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 8, 2021</start_date>
  <completion_date type="Anticipated">July 2025</completion_date>
  <primary_completion_date type="Anticipated">July 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Open label, interventional</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Turn around time for systems biology analysis</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate to systems biology guided therapy</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival base on concordance with recommended treatment</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">74</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Estrogen Receptor-positive Breast Cancer</condition>
  <condition>HER2-negative Breast Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Drug determined by treating oncologist based on recommendation from systems biology analysis.</intervention_name>
    <description>All patients will have a biopsy at the beginning of the trial. The biopsy will be sent for DNA sequencing through FoundationOne(clinical test) and RNA profiling at Fulgent(research test) for determination of activation of various oncogenic pathways and phenotypes. The results will be analyzed and a treatment recommendation will be made to the treating physician based on an algorithm.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologic diagnosis of breast cancer&#xD;
&#xD;
          -  Metastatic or incurable&#xD;
&#xD;
          -  Prior treatment with an anastrozole or letrozole and a CDK4/6 inhibitor&#xD;
&#xD;
          -  Progression while on or within 6 months of stopping the CDK4/6 inhibitor&#xD;
&#xD;
          -  At least one lesion amenable to percutaneous biopsy that is not a purely sclerotic&#xD;
             bone lesion&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
          -  Age 18 or greater&#xD;
&#xD;
          -  Able to provide informed consent and willing to sign an approved consent form that&#xD;
             conforms to federal and institutional guidelines.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior treatment within 2 years with fulvestrant, alpelisib, everolimus, or&#xD;
             capecitabine&#xD;
&#xD;
          -  Comorbid disease other than breast cancer with a life expectancy of less than 2 years&#xD;
&#xD;
          -  Cancer other than breast cancer that is expected to need treatment within 2 years&#xD;
&#xD;
          -  Platelets &lt; 100,000/microliter&#xD;
&#xD;
          -  INR &gt; 1.5&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Stephanie Van Bebber, MSc.</last_name>
    <phone>571-472-0213</phone>
    <email>Stephanie.VanBebber@inova.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Carrie Fischer, MS</last_name>
    <phone>571-472-0224</phone>
    <email>Carrie.Fischer@inova.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Inova Schar Cancer Institute</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Van Bebber, MSc.</last_name>
      <phone>571-472-0213</phone>
      <email>Stephanie.VanBebber@inova.org</email>
    </contact>
    <contact_backup>
      <last_name>Carrie Fischer, MS</last_name>
      <phone>571-471-0224</phone>
      <email>Carrie.Fischer@inova.org</email>
    </contact_backup>
    <investigator>
      <last_name>Adam Cohen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 7, 2021</study_first_submitted>
  <study_first_submitted_qc>July 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 16, 2021</study_first_posted>
  <last_update_submitted>October 13, 2021</last_update_submitted>
  <last_update_submitted_qc>October 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

